Published in

American Association of Immunologists, The Journal of Immunology, 1_Supplement(210), p. 75.16-75.16, 2023

DOI: 10.4049/jimmunol.210.supp.75.16

Links

Tools

Export citation

Search in Google Scholar

Anamnestic expansion of Omicron-reactive CD8 +T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Restricted immune responses to SARS-CoV-2 mRNA vaccination have been observed frequently in individuals suffering from various immunodeficiencies. With increased antibody evasion properties of rising Omicron subvariants, there is a need to assess if other components of adaptive immunity generate resilient responses against SARS-CoV-2 across immunodeficient states. Here we assessed T cell responses of n=279 individuals covering five different immunodeficiencies and healthy controls before and after booster vaccination and - in a subset of patients - additional Omicron infection. We observed significantly increased Omicron-reactive T cell responses upon booster vaccination, particularly in initial poor responders, across all patient groups. Overall T cell composition shifted towards an increased CD8/CD4-ratio, which was accompanied by a more pronounced cytotoxic profile. Moreover, Omicron-reactive T cell responses showed signs of longevity represented by a novel T EMRAsubpopulation with stem-cell-like characteristics and increased proliferative capacity. Regardless of underlying immunodeficiency, booster-vaccinated and Omicron-infected individuals were protected against severe disease and exhibited ameliorated and diversified T cell responses directed explicitly against Omicron, despite a solid immunological imprint of multiple wildtype Wuhan-based vaccine doses. Supported by grants from SciLifeLab National COVID-19 Research Program and financed by the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Nordstjernan AB, Region Stockholm (Clinical research position-, ALF-, and CIMEDgrants). TRM is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project: 496946670).